Welcome to our dedicated page for AEQUUS PHARMACEUTICAL news (Ticker: AQSZF), a resource for investors and traders seeking the latest updates and insights on AEQUUS PHARMACEUTICAL stock.
Aequus Pharmaceuticals Inc. (AQSZF) is a specialty pharmaceutical company focused on developing and commercializing high-quality products. Founded in 2015, the company has grown multiple products in therapeutic areas like Ophthalmology, Optometry, Transplant, and Rare Disease. Aequus plans to expand its Canadian commercial platform through sales, marketing, and strategic partnerships.
The company's Evolve® range of products is currently on hold in Canada due to a switch in MDSAP provider by Medicom Healthcare (UK). Once the certification process is complete, sales will resume, reaffirming Aequus' commitment to delivering innovative solutions.
With a dedication to patient well-being and a focus on enhancing the Canadian marketplace, Aequus Pharmaceuticals is poised for continued growth and success.
Aequus Pharmaceuticals (AQSZF) reported its Third Quarter 2022 financials, revealing a significant drop in revenue to $268,970 from $669,000 in Q3 2021. Year-to-date revenue also declined by 53% to $826,944. The company recorded a net loss of $500,471, a 31% increase from the previous year, totaling $2,189,466 year-to-date, marking a 48% increase. Cost-cutting measures reduced general administration expenses, which dropped to $353,573 from $488,039 in Q3 2021. Aequus anticipates product launches in mid-2023 to aid in revenue recovery.
Aequus Pharmaceuticals (OTCQB: AQSZF) announced the termination of its promotional service agreement with Sandoz Canada for Tacrolimus Immediate Release and PrVistitan, effective December 31, 2022. Following this, Aequus anticipates receiving a 'Notice of Compliance' from Health Canada for Zimed® PF, a preservative-free bimatoprost solution, by year-end 2022. This new product aims to serve patients with open-angle glaucoma. The company expects that Zimed® PF will surpass previous revenues from Sandoz’s products, although its launch may affect short-term revenues.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) has reported its financial results for the second quarter of 2022, revealing a significant revenue decline of 43% year-over-year, amounting to $346,494. The company also experienced a 61% increase in net losses, totaling $772,110. Despite these challenges, Aequus appointed Rabin Ramanjooloo as Director of Operations, anticipating his expertise will aid in upcoming product launches. The company remains optimistic about growth prospects in 2023 and beyond due to strategic investments and potential collaborations.
Doug Janzen announced the acquisition of 100,000 Common Shares in Aequus Pharmaceuticals on July 19, 2022, through the TSX Venture Exchange. He purchased 99,000 shares at $0.07 each and 1,000 shares at $0.08, totaling $7,010. Following a prior issuance of shares, Janzen's ownership fell below 10%, exempting him from early warning requirements under NI 62-103. After the acquisition, he held approximately 9.08% of total outstanding shares. The acquisition was made for investment purposes, and further early warning reports will only be filed if his holdings exceed 10%.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) will resume trading on the TSX Venture Exchange on July 14, 2022, following a prior announcement on July 6, 2022. CEO Doug Janzen expressed confidence in taking measures to prevent past issues from recurring and highlighted new product developments. The company aims to expand its product offerings in the coming months, emphasizing a proactive approach to business risks.
Aequus Pharmaceuticals has signed an exclusive distribution agreement with SCOPE Ophthalmics, securing Canadian commercial rights to 10 preservative-free ophthalmology products, including the OPTASE® range for dry eyes. This partnership aims to enhance the portfolio of eye care solutions available in Canada. Aequus will manage the marketing, distribution, and sales of these products, with plans to launch select items later this year. This deal positions Aequus as a leading provider of preservative-free therapies in Canada, further expanding its reach in the ophthalmology market.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) reported its financial results for Fiscal 2021 and Q1 2022, with total revenue in Fiscal 2021 reaching $2,714,698, a notable increase from $2,592,613 in 2020. The company experienced a loss of $1,809,592 in 2021. Q1 2022 revenue declined to $302,280 from $491,821 in Q1 2021. The delay in filing annual financial statements led to a cease trade order, but management believes they are now compliant. A loan of $2,000,000 was secured to mitigate revenue weakness.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) announced delays in filing its audited annual financial statements for the fiscal year ending December 31, 2021, and related quarterly financials. CEO Doug Janzen stated that the delay is due to additional queries from their primary commercial partner's auditors and is not attributed to the company's internal processes. Aequus aims to file both Annual and Quarterly Disclosures soon, once the necessary information is received, to lift the Cease Trade Order. Further updates are expected shortly.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) announced a delay in filing its audited annual financial statements for the fiscal year ending December 31, 2021, due to the need for confidential information from partners. CEO Doug Janzen expressed frustration over external factors affecting the audit process. Aequus aims to file the required documents by May 30, 2022, to lift the Cease Trade Order. Despite the delays, the company remains focused on its business strategy in ophthalmology and transplant, continuing to develop specialized therapeutic products.
Aequus Pharmaceuticals Inc. (AQSZF) reports a delay in filing its audited annual financial statements for the fiscal year ended December 31, 2021, due to unexpected regulatory changes and COVID-related staffing issues at its audit firm. A cease trade order is anticipated next week. CEO Doug Janzen expressed frustration but remains optimistic about strong revenue in 2021, having entered a loan agreement with the company to support growth. The company aims to file the Annual Disclosure by May 20, 2022, and appreciates the cooperation of its commercial partners during this audit process.
FAQ
What is the market cap of AEQUUS PHARMACEUTICAL (AQSZF)?
What is Aequus Pharmaceuticals Inc. focused on?
When will sales of Evolve® products resume in Canada?
What is Aequus' commitment to patients in Canada?
When was Aequus Pharmaceuticals founded?
In which therapeutic areas has Aequus grown products?
How does Aequus plan to expand its Canadian platform?
Why are Evolve® products currently on hold in Canada?
What sets Aequus Pharmaceuticals apart in the market?
Where can I find more information about Aequus Pharmaceuticals?
What is Aequus Pharmaceuticals' stock symbol?
